Novartis Q4 Results
Content
Click below to navigate
through the document
Net debt increased by USD 3.0bn mainly due to dividends and share
buybacks, partly offset by FCF
FINANCIAL PROFILE
↓
↑
Company overview
Financial review
USDbn
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Abbreviations
References
-7.2
-7.3
-8.6
Dec 31, 2022
Dividends
Treasury share
transactions, net
-3.0
-3.3
M&A/Intangible
assets
transactions, net
1 Reflects USD 0.7bn cash and cash equivalents, and USD 3.7bn of financial debts of Sandoz at the time of the spin-off.
□ NOVARTIS | Reimagining Medicine.
-10.2
3.0
13.2
Free Cash Flow
Net debt Sandoz 1
Dec 31, 2023
Novartis Q4 Results | January 31, 2024
44View entire presentation